Retatrutide appears to be a new treatment in the fight against obesity. This novel drug, classified as a dual GLP-1 and GIP receptor agonist, exhibits promising results in investigations. By activating these receptors, Retatrutide suppresses appetite, {promotesenergy expenditure, and ultimately leads to significant reduction in body mass. While st… Read More